Why the study?
Do PPAR-γ activators (thiazolidinediones) reduce cardiovascular morbidity and mortality?
Design
Review
Authors
Loading...
Thiazolidinediones should not yet be used for CV risk reduction; leaves open need for targeted outcome trials.
Do PPAR-γ activators (thiazolidinediones) reduce cardiovascular morbidity and mortality?
Despite favorable metabolic and vascular effects, thiazolidinediones lack conclusive evidence for reducing cardiovascular events, highlighting the need for ongoing trials to clarify their therapeutic role.
Huang et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: